利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

147 条记录 (耗时 0.031 秒)

    USE OF CANNABIDIOL IN COMBINATION WITH ANTIBIOTICS
    2.
    发明申请
    USE OF CANNABIDIOL IN COMBINATION WITH ANTIBIOTICS 有权

    公开(公告)号：US20220183997A1

    公开(公告)日：2022-06-16

    申请号：US17435892

    申请日：2020-03-03

    申请人： GW Pharma Limited

    发明人： Geoffrey GUY ,  Volker KNAPPERTZ

    IPC分类号： A61K31/05 ,  A61K38/12 ,  A61K31/496 ,  A61K31/7048 ,  A61K31/7036 ,  A61K38/14 ,  A61K31/352 ,  A61P31/04

    摘要： The present invention relates to the use of cannabidiol (CBD), a phytocannabinoid which is naturally produced by Cannabis sativa plants or can be made synthetically, for use in combination with antibiotics. Preferably the CBD increases the bactericidal action of antibiotics. More preferably the bactericidal action is used against Gram-negative bacteria. In a further embodiment the CBD increases the antibiotic effects of Kanamycin in Gram-positive bacteria. Such combinations may help overcome antibiotic resistance. Preferably the CBD used is in the form of a highly purified extract of Cannabis such that the CBD is present at greater than 95% of the total extract (w/w) and the other components of the extract are characterised. In particular tetrahydrocannabinol (THC) has been substantially removed to a level of not more than 0.1% (w/w). Alternatively, it is a synthetically produced CBD. In use the CBD is used concomitantly with one or more antibiotics. Alternatively, the CBD may be formulated for administration separately, sequentially or simultaneously with one or more antibiotics or the combination may be provided in a single dosage form. Where the CBD is formulated for administration separately, sequentially or simultaneously it may be provided as a kit or together with instructions to administer the one or more components in the manner indicated.

    Pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD)
    3.
    发明授权
    Pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD) 有权

    公开(公告)号：US11318109B2

    公开(公告)日：2022-05-03

    申请号：US16709401

    申请日：2019-12-10

    申请人： GW Pharma Limited ,  Otsuka Pharmaceutical Co., Limited

    发明人： Benjamin Whalley ,  Claire Williams ,  Gary Stephens ,  Thomas Hill

    IPC分类号： A61K31/05 ,  A61K36/185 ,  A61K31/352 ,  A61K31/045 ,  A61K31/353 ,  A61K45/06

    摘要： This invention relates to a pharmaceutical composition comprising or consisting essentially of the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD). The composition is particularly safe and efficacious for use in the treatment of neurological conditions, characterized by hyper-excitability of the central nervous system, convulsions or seizures such as occur in epilepsy. Preferably the CBDV and the CBD are present with at least one non-cannabinoid component of cannabis such as one or more terpenes or a terpene fraction. More particularly the composition further comprises one or more cannabichromene type compounds. Particularly cannabichromene propyl variant (CBCV) and/or cannabichromene (CBC). More particularly still the composition is absent or substantially absent of other cannabinoids, including in particular tetrahydrocannabinol (THC) and tetrahydrocannabivarin (THCV), which would normally be present in significant amounts in cannabis chemotypes bred to contain a significant amount of CBDV and/or CBD.

    USE OF CANNABINOIDS IN THE TREATMENT OF MENTAL DISORDERS
    6.
    发明申请
    USE OF CANNABINOIDS IN THE TREATMENT OF MENTAL DISORDERS 审中-公开

    公开(公告)号：US20180344660A1

    公开(公告)日：2018-12-06

    申请号：US15757899

    申请日：2016-09-08

    申请人： GW Pharma Limited

    发明人： Philip Robson ,  Geoffrey Guy ,  Stephen Wright ,  Emma Cheetham ,  Dominic Schiller

    IPC分类号： A61K31/05 ,  A61K31/496 ,  A61K31/5513 ,  A61K31/554 ,  A61K31/519 ,  A61K31/40 ,  A61P25/18

    CPC分类号： A61K31/05 ,  A61K31/40 ,  A61K31/496 ,  A61K31/519 ,  A61K31/551 ,  A61K31/5513 ,  A61K31/554 ,  A61P25/18 ,  A61K2300/00

    摘要： This invention relates to the use of CBD to treat mental disorders. For example it can be used as an adjunct therapy to treat positive symptoms in mental disorders such as schizophrenia and related disorders; or as an adjunct therapy in combination with olanzapine to treat both positive and negative symptoms in mental disorders such as schizophrenia and related disorders; or as an adjunct therapy in combination with olanzapine to treat negative symptoms in mental disorders such as schizophrenia and related disorders; or as an adjunct therapy to treat anhedonia/asociality in mental disorders such as schizophrenia and related disorders; or as an adjunct therapy to treat avolition/apathy in mental disorders such as schizophrenia and related disorders; or as an adjunct therapy to treat disturbance of attention in mental disorders such as schizophrenia and related disorders; or as a monotherapy or as an adjunct therapy to treat one or more distinct sub-domains of negative symptoms selected from: i) avolition/apathy; ii) anhedonia/asociality and iii) disturbance of attention; or as an adjunct therapy to treat cognitive symptoms, particularly working memory, motor speed and executive function in mental disorders such as schizophrenia and related disorders. There may additionally be provided compositions comprising CBD in combination with one or more antipsychotics such as olanzapine and quetiapine. In particular the invention relates to the treatment of schizophrenia or related psychotic disorders, more particularly still those which are considered to be treatment resistant.

    ACTIVE PHARMACEUTICAL INGREDIENT (API) COMPRISING CANNABINOIDS FOR USE IN THE TREATMENT OF CANCER
    9.
    发明申请
    ACTIVE PHARMACEUTICAL INGREDIENT (API) COMPRISING CANNABINOIDS FOR USE IN THE TREATMENT OF CANCER 有权

    公开(公告)号：US20170143642A1

    公开(公告)日：2017-05-25

    申请号：US15321766

    申请日：2015-06-26

    申请人： GW Pharma Limited

    发明人： Colin Stott ,  Marnie Duncan ,  Thomas Hill

    IPC分类号： A61K31/05

    CPC分类号： A61K31/05 ,  A61K2300/00

    摘要： The present invention relates to an active pharmaceutical ingredient (API) which comprises or consists essentially of cannabidiol (CBD) and one other cannabinoid selected from cannabigerol (CBG), cannabigerolic acid (CBGA), cannabidiolic acid (CBDA), and tetrahydrocannabivarin (THCV) for use as a medicament, and more particularly, for use in the treatment of cancer. These combinations have shown themselves to be synergistic in treating one or more of: breast cancer; liver cancer; lung cancer; pancreatic cancer; melanoma; ovarian cancer; gastric cancer; renal cancer or bladder cancer. Two particularly favored API combinations are: cannabidiol (CBD) and cannabigerol (CBG); and cannabidiolic (CBD) and tetrahydrocannabivarin (THCV).